Search research articles
Contact Us
Filters
Showing results (21-30 of 47) with videos related to
Page
of 5
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
June 21, 2017
Tumor Suppressor microRNAs Contribute to the Regulation of PD-L1 Expression in Malignant Pleural Mesothelioma
Steven C Kao, Yuen Yee Cheng, Marissa Williams, et al.
Oncotarget
|
June 19, 2015
Combining BET and HDAC inhibitors synergistically induces apoptosis of melanoma and suppresses AKT and YAP signaling
Anja Heinemann, Carleen Cullinane, Ricardo De Paoli-Iseppi, et al.
Plos One
|
October 3, 2012
The genomic landscape of TP53 and p53 annotated high grade ovarian serous carcinomas from a defined founder population associated with patient outcome
Paulina M Wojnarowicz, Kathleen Klein Oros, Michael C J Quinn, et al.
Lung Cancer (Amsterdam, Netherlands)
|
May 31, 2015
PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma
Wendy A Cooper, Thang Tran, Ricardo E Vilain, et al.
Cancer Research
|
June 28, 2017
Targeting Adenosine in BRAF-Mutant Melanoma Reduces Tumor Growth and Metastasis
Arabella Young, Shin Foong Ngiow, Jason Madore, et al.
Oncotarget
|
August 26, 2015
Targeting activating mutations of EZH2 leads to potent cell growth inhibition in human melanoma by derepression of tumor suppressor genes
Jessamy C Tiffen, Dilini Gunatilake, Stuart J Gallagher, et al.
European Journal of Immunology
|
November 12, 2024
Type I Interferon Drives a Cellular State Inert to TCR-Stimulation and Could Impede Effective T-Cell Differentiation in Cancer
Dillon Corvino, Martin Batstone, Brett G M Hughes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 31, 2018
CD103<sup>+</sup> Tumor-Resident CD8<sup>+</sup> T Cells Are Associated with Improved Survival in Immunotherapy-Naïve Melanoma Patients and Expand Significantly During Anti-PD-1 Treatment
Jarem Edwards, James S Wilmott, Jason Madore, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 18, 2017
Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma
Ricardo E Vilain, Alexander M Menzies, James S Wilmott, et al.
Cancer Immunology Research
|
March 22, 2019
CD96 Is an Immune Checkpoint That Regulates CD8<sup>+</sup> T-cell Antitumor Function
Deepak Mittal, Ailin Lepletier, Jason Madore, et al.
Page
of 5
Search research articles
Search
Showing results (21-30 of 47) with videos related to
Sort By:
Page
of 5
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
June 21, 2017
Tumor Suppressor microRNAs Contribute to the Regulation of PD-L1 Expression in Malignant Pleural Mesothelioma
Steven C Kao, Yuen Yee Cheng, Marissa Williams, et al.
Oncotarget
|
June 19, 2015
Combining BET and HDAC inhibitors synergistically induces apoptosis of melanoma and suppresses AKT and YAP signaling
Anja Heinemann, Carleen Cullinane, Ricardo De Paoli-Iseppi, et al.
Plos One
|
October 3, 2012
The genomic landscape of TP53 and p53 annotated high grade ovarian serous carcinomas from a defined founder population associated with patient outcome
Paulina M Wojnarowicz, Kathleen Klein Oros, Michael C J Quinn, et al.
Lung Cancer (Amsterdam, Netherlands)
|
May 31, 2015
PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma
Wendy A Cooper, Thang Tran, Ricardo E Vilain, et al.
Cancer Research
|
June 28, 2017
Targeting Adenosine in BRAF-Mutant Melanoma Reduces Tumor Growth and Metastasis
Arabella Young, Shin Foong Ngiow, Jason Madore, et al.
Oncotarget
|
August 26, 2015
Targeting activating mutations of EZH2 leads to potent cell growth inhibition in human melanoma by derepression of tumor suppressor genes
Jessamy C Tiffen, Dilini Gunatilake, Stuart J Gallagher, et al.
European Journal of Immunology
|
November 12, 2024
Type I Interferon Drives a Cellular State Inert to TCR-Stimulation and Could Impede Effective T-Cell Differentiation in Cancer
Dillon Corvino, Martin Batstone, Brett G M Hughes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 31, 2018
CD103<sup>+</sup> Tumor-Resident CD8<sup>+</sup> T Cells Are Associated with Improved Survival in Immunotherapy-Naïve Melanoma Patients and Expand Significantly During Anti-PD-1 Treatment
Jarem Edwards, James S Wilmott, Jason Madore, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 18, 2017
Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma
Ricardo E Vilain, Alexander M Menzies, James S Wilmott, et al.
Cancer Immunology Research
|
March 22, 2019
CD96 Is an Immune Checkpoint That Regulates CD8<sup>+</sup> T-cell Antitumor Function
Deepak Mittal, Ailin Lepletier, Jason Madore, et al.
Page
of 5